Prostate cancer - Revision history

Michael: vauthors

2020-05-24T20:29:51Z

vauthors

← Older revision		Revision as of 20:29, 24 May 2020
Line 242:		Line 242:

	===Situations where prostate adenocarcinoma may be missed===		===Situations where prostate adenocarcinoma may be missed===
	Key reasons for false negative prostate samples<ref>{{cite journal \|~~vauthors~~=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>:		Key reasons for false negative prostate samples<ref>{{cite journal \|authors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>:
	*Tissue artefacts (try levels and/or IHC):		*Tissue artefacts (try levels and/or IHC):
	**Crush artefact		**Crush artefact

Sarah A: /* Situations where prostate adenocarcinoma may be missed */

2020-03-05T15:59:46Z

Situations where prostate adenocarcinoma may be missed

← Older revision		Revision as of 15:59, 5 March 2020
Line 256:		Line 256:
	**[[PIN-like adenocarcinoma]]		**[[PIN-like adenocarcinoma]]
	**Microcystic adenocarcinoma		**Microcystic adenocarcinoma
	*Single cells of Gleason 5 adenocarcinoma (missed or mistaken for lymphocytes; try IHC)		*Single cells of Gleason 5 adenocarcinoma (missed or mistaken for lymphocytes; try IHC for cytokeratins, prostatic and/or hematologic markers)
	*Treatment effect (check clinical information and look for treatment effect in benign glands)		*Treatment effect (check clinical information and look for treatment effect in benign glands)

Sarah A: /* Situations where prostate adenocarcinoma may be missed{{cite journal |vauthors=Yang C, Humphrey PA |title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma |journal=Arch. Pathol. Lab. Med. |volume=144 |issue=3 |pages=326–334 |date=March 2020 |pmid=31729886 |doi=10.5858/arpa.2019-0456-RA |url=}} */

2020-03-05T15:59:09Z

Situations where prostate adenocarcinoma may be missed{{cite journal |vauthors=Yang C, Humphrey PA |title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma |journal=Arch. Pathol. Lab. Med. |volume=144 |issue=3 |pages=326–334 |date=March 2020 |pmid=31729886 |doi=10.5858/arpa.2019-0456-RA |url=}}

← Older revision		Revision as of 15:59, 5 March 2020
Line 241:		Line 241:
	Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.		Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.

	===Situations where prostate adenocarcinoma may be missed<ref>{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>~~===~~		===Situations where prostate adenocarcinoma may be missed===
			Key reasons for false negative prostate samples<ref>{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>:
	*Tissue artefacts (try levels and/or IHC):		*Tissue artefacts (try levels and/or IHC):
	**Crush artefact		**Crush artefact

Sarah A: /* Situations where prostate adenocarcinoma may be missed{{cite journal |vauthors=Yang C, Humphrey PA |title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma |journal=Arch. Pathol. Lab. Med. |volume=144 |issue=3 |pages=326–334 |date=March 2020 |pmid=31729886 |doi=10.5858/arpa.2019-0456-RA |url=}} */

2020-03-05T15:46:43Z

← Older revision		Revision as of 15:46, 5 March 2020
Line 242:		Line 242:

	===Situations where prostate adenocarcinoma may be missed<ref>{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>===		===Situations where prostate adenocarcinoma may be missed<ref>{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>===
	*Tissue artefacts (try levels and/or IHC)		*Tissue artefacts (try levels and/or IHC):
	**Crush artefact ~~obscuring architectural or cytologic features~~		**Crush artefact
	**Thick ~~section~~		**Thick sections
	**~~Aberration in~~ H&E staining ~~obscuring cytologic features~~		**Aberrant H&E staining
	**Freezing artefact		**Freezing artefact
	*Minimal adenocarcinoma		**Cautery
			*Minimal adenocarcinoma (less than 1mm long or involving less than 5% of a core biopsy):
	*Prostatic adenocarcinoma variants that mimic benign:		*Prostatic adenocarcinoma variants that mimic benign:
	**[[Atrophic prostate carcinoma]].		**[[Atrophic prostate carcinoma]]
	**[[Pseudohyperplastic adenocarcinoma]].		**[[Pseudohyperplastic adenocarcinoma]]
	**[[Foamy gland adenocarcinoma]].		**[[Foamy gland adenocarcinoma]]
	**[[PIN-like adenocarcinoma]].		**[[PIN-like adenocarcinoma]]
	*Single~~-cell~~ adenocarcinoma		**Microcystic adenocarcinoma
	*Treatment effect		*Single cells of Gleason 5 adenocarcinoma (missed or mistaken for lymphocytes; try IHC)
			*Treatment effect (check clinical information and look for treatment effect in benign glands)

	===Prostate cancer grading===		===Prostate cancer grading===

Sarah A: /* Situations where prostate adenocarcinoma may be missed{{cite journal |vauthors=Yang C, Humphrey PA |title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma |journal=Arch. Pathol. Lab. Med. |volume=144 |issue=3 |pages=326–334 |date=March 2020 |pmid=31729886 |doi=10.5858/arpa.2019-0456-RA |url=}} */

2020-03-05T15:37:12Z

← Older revision		Revision as of 15:37, 5 March 2020
Line 241:		Line 241:
	Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.		Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.

	===Situations where prostate adenocarcinoma may be missed{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}===		===Situations where prostate adenocarcinoma may be missed<ref>{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}</ref>===
	*Tissue artefacts (try levels and/or IHC)		*Tissue artefacts (try levels and/or IHC)
	**Crush artefact obscuring architectural or cytologic features		**Crush artefact obscuring architectural or cytologic features

Sarah A: /* Prostatic adenocarcinoma variants that mimic benign */

2020-03-05T15:36:42Z

Prostatic adenocarcinoma variants that mimic benign

← Older revision		Revision as of 15:36, 5 March 2020
Line 241:		Line 241:
	Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.		Memory device: '''AAABBRS''' = atrophy, adenosis, adenosis (sclerosing), basal cell hyperplasia, bulbourethral gland, radiation, seminal vesicles.

	===Prostatic adenocarcinoma variants that mimic benign~~===~~		===Situations where prostate adenocarcinoma may be missed{{cite journal \|vauthors=Yang C, Humphrey PA \|title=False-Negative Histopathologic Diagnosis of Prostatic Adenocarcinoma \|journal=Arch. Pathol. Lab. Med. \|volume=144 \|issue=3 \|pages=326–334 \|date=March 2020 \|pmid=31729886 \|doi=10.5858/arpa.2019-0456-RA \|url=}}===
	*[[Atrophic prostate carcinoma]].		*Tissue artefacts (try levels and/or IHC)
	*[[Pseudohyperplastic adenocarcinoma]].		**Crush artefact obscuring architectural or cytologic features
	*[[Foamy gland adenocarcinoma]].		**Thick section
	*[[PIN-like adenocarcinoma]].		**Aberration in H&E staining obscuring cytologic features
			**Freezing artefact
			*Minimal adenocarcinoma
			*Prostatic adenocarcinoma variants that mimic benign:
			**[[Atrophic prostate carcinoma]].
			**[[Pseudohyperplastic adenocarcinoma]].
			**[[Foamy gland adenocarcinoma]].
			**[[PIN-like adenocarcinoma]].
			*Single-cell adenocarcinoma
			*Treatment effect

	===Prostate cancer grading===		===Prostate cancer grading===

Michael: /* Active surveillance */

2019-03-16T23:39:10Z

Active surveillance

← Older revision		Revision as of 23:39, 16 March 2019
Line 83:		Line 83:
	Clinical criteria:		Clinical criteria:
	*PSA <= 10 ng/mL.<ref name=pmid22314081/>		*PSA <= 10 ng/mL.<ref name=pmid22314081/>
			*Negative DRE.

	==Gross==		==Gross==

Michael: /* Transurethral resection of prostate */

2017-06-27T15:58:58Z

Transurethral resection of prostate

← Older revision		Revision as of 15:58, 27 June 2017
Line 386:		Line 386:
	Prostate Tissue, Transurethral Resection of Prostate (TURP):		Prostate Tissue, Transurethral Resection of Prostate (TURP):
	- ADENOCARCINOMA, Gleason score 6/10 (3+3);		- ADENOCARCINOMA, Gleason score 6/10 (3+3);
	- Approximately 3% of tissue involved;		-- Approximately 2% of tissue involved;
	- Please see tumour summary.		-- Please see tumour summary.

			Comment:
			The World Health Organization (WHO) grade is: 1 out of 5.
			</pre>

			<pre>
			Prostate Tissue, Transurethral Resection of Prostate (TURP):
			- ADENOCARCINOMA, Gleason score 7/10 (3+4);
			-- Approximately 4% of tissue involved;
			-- Please see tumour summary.
			- Benign inflamed urothelium.

			Comment:
			The World Health Organization (WHO) grade is: 2 out of 5. Gleason pattern 3 represents 90% of the tumour, and Gleason pattern 4 represents 10% of the tumour.
	</pre>		</pre>

Michael at 03:12, 11 October 2016

2016-10-11T03:12:08Z

← Older revision		Revision as of 03:12, 11 October 2016
Line 253:		Line 253:
	====Surgical margins====		====Surgical margins====
	{{Main\|Surgical margins}}		{{Main\|Surgical margins}}
	*Positive is ''tumour touching ink''.† <ref name=pmid22578729>{{Cite journal \| last1 = Lu \| first1 = J. \| last2 = Wirth \| first2 = GJ. \| last3 = Wu \| first3 = S. \| last4 = Chen \| first4 = J. \| last5 = Dahl \| first5 = DM. \| last6 = Olumi \| first6 = AF. \| last7 = Young \| first7 = RH. \| last8 = McDougal \| first8 = WS. \| last9 = Wu \| first9 = CL. \| title = A close surgical margin after radical prostatectomy is an independent predictor of recurrence. \| journal = J Urol \| volume = 188 \| issue = 1 \| pages = 91-7 \| month = Jul \| year = 2012 \| doi = 10.1016/j.juro.2012.02.2565 \| PMID = 22578729 }}</ref>		*Positive is ''tumour touching [[ink]]''.† <ref name=pmid22578729>{{Cite journal \| last1 = Lu \| first1 = J. \| last2 = Wirth \| first2 = GJ. \| last3 = Wu \| first3 = S. \| last4 = Chen \| first4 = J. \| last5 = Dahl \| first5 = DM. \| last6 = Olumi \| first6 = AF. \| last7 = Young \| first7 = RH. \| last8 = McDougal \| first8 = WS. \| last9 = Wu \| first9 = CL. \| title = A close surgical margin after radical prostatectomy is an independent predictor of recurrence. \| journal = J Urol \| volume = 188 \| issue = 1 \| pages = 91-7 \| month = Jul \| year = 2012 \| doi = 10.1016/j.juro.2012.02.2565 \| PMID = 22578729 }}</ref>
	**"Close" margins (<0.1 mm) have an increased recurrence risk.<ref name=pmid22578729/>		**"Close" margins (<0.1 mm) have an increased recurrence risk.<ref name=pmid22578729/>

Michael: /* Transurethral resection of prostate */

2016-10-04T16:54:13Z

Transurethral resection of prostate

← Older revision		Revision as of 16:54, 4 October 2016
Line 385:		Line 385:
	<pre>		<pre>
	Prostate Tissue, Transurethral Resection of Prostate (TURP):		Prostate Tissue, Transurethral Resection of Prostate (TURP):
	- ADENOCARCINOMA, Gleason ~~Score~~ 6/10 (3+3);		- ADENOCARCINOMA, Gleason score 6/10 (3+3);
	- Approximately 5% of ~~Tissue Involved~~;		- Approximately 3% of tissue involved;
	- Please ~~See Tumor~~ summary.		- Please see tumour summary.
	</pre>		</pre>